wow! PennyStock101 (org) has helped my account tremendously. Lots of people hate on them but they have been making me money with their otcmarket, nyse and nasdaq alerts. search them up!
Jut sold my trading shares at $42. Could go higher, but the gain on the shares were too much not to take some profits. If it fell back into the mid 30s I would buy back the shares.
Management also said the right things during the conference call. No wasteful acquisitions planned and still plenty of organic growth left to focus on.
It appears the confluence of increased numbers of insured under ACA, the clear superiority of 3D Tomo and the Icahn management team are finally propelling HOLX to the growth it deserves.
Congratulations to the management team and all HOLX longs.
Sentiment: Strong Buy
Hologic bought a computer aided diagnosisdiagnosis (CAD) company a few years back and left ICAD out there to take a lot of the other pie and have a 40 percent market share. CAD isabout to go through a huge 3D upgrade cycle and ICAD is sitting close to recent lows due to a hiccup in Xoft reinbursement. A non radioactive isotope way to treat localized cancer. Xoft is still groungbreaking tech ant leaves ICAD way cheap ripe for an aquisition or at least a good speculative play.
For the last 8 days we have had above average volume. I wonder if we have a slight change of the major holders. Any major players who bought before last May would have some major gains that are now long term gains and maybe they are booking some profits with the new quarter.
Since it has almost been 3 months since this target price increase and with HOLX getting close to 39, I think its about time for Goldman to have another target price increase, $45 sounds good.
You would do well to listen to the CEO presentation yesterday. He said that in some cases coverage is still being worked out, which is regrettable. However, he said that take up is accelerating. The out of pocket difference is some $100, isn't it, which seems like nothing for such a vital protection.
My wife just went to get her mammogram and even though they have a 3-D machine they have a sign saying most insurances won't cover using it, including the regions 2 dominant insurance companies.
This is a section of an article from the Pittsburgh Post Gazette.
Dr. Poller said Allegheny and UPMC have tomosynthesis technology. Although Medicare now reimburses the cost, insurers Highmark and UPMC Health Plan do not cover the screenings, so they are not being used regularly.
In its general policy guidelines, Highmark says, “There is limited scientific evidence supporting efficacy, therefore Digital Breast Tomosynthesis is considered experimental/investigational and non-covered.”
At UPMC Health Plan, Stephen Perkins, vice president of medical affairs, prepared a statement reinforcing the company’s commitment to effective screening and early detection of breast cancer, adding, “We are closely following the scientific literature, as it relates to the use of 3-D Mammography, or tomosynthesis, and are in discussions with our specialty physicians regarding if, and when, evidence for this methodology is strong enough to support reimbursement.”
While many other stocks are getting the hype and the forum posts, HOLX is providing great returns. HOLX is up 35% ytd vs. 3% for S&P and even the much hyped IBB is up only 20%.
Even with all the jawboning that Icahn has provided for Apple, HOLX is still beating AAPL for one year performance.